Paper Details

  1. Home
  2. Paper Details

<i>DPYD</i> Genotyping in Patients Who Have Planned Cancer Treatment With Fluoropyrimidines: A Health Technology Assessment.

Author:

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This health technology assessment evaluated the clinical validity and utility of DPYD genotyping for patients undergoing fluoropyrimidine cancer treatment. It found that DPYD genotyping can identify individuals at higher risk of severe toxicity, allowing for dose adjustments and improved safety. The assessment also considered the effectiveness of reduced fluoropyrimidine doses, cost-effectiveness, budget impact, and patient preferences.
Paper Details　
Original Abstract of the Article :
Label="BACKGROUND" NlmCategory="BACKGROUND">Fluoropyrimidine drugs (such as 5-fluorouracil and capecitabine) are used to treat different types of cancer. However, these drugs may cause severe toxicity in about 10% to 40% of patients. A deficiency in the dihydropyrimidine dehydrogenase (DPD) enzyme, ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8382304/

データ提供：米国国立医学図書館（NLM）

DPYD Genotyping: A Tool for Personalized Fluoropyrimidine Therapy

Fluoropyrimidine drugs, like 5-fluorouracil and capecitabine, are widely used in cancer treatment. However, these medications can cause severe toxicity in some patients. This study examines the role of DPYD genotyping, a genetic test that identifies variants associated with DPD deficiency, in predicting and mitigating the risk of fluoropyrimidine-related toxicity. The researchers conducted a health technology assessment to evaluate the clinical validity, utility, and cost-effectiveness of DPYD genotyping.

DPYD Genotyping: A Guidepost for Personalized Cancer Treatment

The study highlights the potential of DPYD genotyping to personalize fluoropyrimidine therapy. By identifying patients at higher risk of toxicity, DPYD genotyping can guide treatment decisions, allowing for dose adjustments or alternative therapies. It's like having a map of the desert, highlighting areas of potential danger and guiding travelers to safer routes.

Empowering Personalized Cancer Care

DPYD genotyping has the potential to improve the safety and effectiveness of fluoropyrimidine therapy by allowing for personalized treatment strategies. This approach, like a well-stocked oasis, provides the resources and knowledge needed to navigate the complexities of cancer treatment, ensuring a smoother and safer journey for patients.

Dr.Camel's Conclusion

This study emphasizes the importance of personalized medicine in cancer treatment. DPYD genotyping, like a compass guiding a traveler through the desert, can help clinicians personalize fluoropyrimidine therapy, minimizing the risk of toxicity and optimizing treatment outcomes.

Date :
  1. Date Completed 2021-10-28
  2. Date Revised 2022-05-31
Further Info :

Pubmed ID

34484488

DOI: Digital Object Identifier

PMC8382304

Related Literature

Article Analysis
・Side Effects of capecitabine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.